Statements (68)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
RNA interference
|
| gptkbp:appointed_by |
subcutaneous injection
|
| gptkbp:approves |
gptkb:2021
gptkb:FDA |
| gptkbp:availability |
prescription only
|
| gptkbp:class |
lipid-lowering agent
|
| gptkbp:clinical_trial |
gptkb:ORION-1
gptkb:ORION-2 gptkb:ORION-3 gptkb:ORION-4 Phase III hyperlipidemia positive outcomes |
| gptkbp:contraindication |
hypersensitivity to inclisiran
|
| gptkbp:developed_by |
gptkb:The_Medicines_Company
|
| gptkbp:dosage_form |
injection
|
| gptkbp:duration |
ongoing
|
| gptkbp:education |
monitoring for side effects
importance of adherence diet and lifestyle changes |
| gptkbp:effective_date |
December 2020
|
| gptkbp:enacted_by |
six months
|
| gptkbp:financial_performance |
stable for 24 months
|
| gptkbp:frequency |
twice a year
|
| gptkbp:future_plans |
pediatric studies
combination therapies long-term efficacy studies |
| https://www.w3.org/2000/01/rdf-schema#label |
inclisiran
|
| gptkbp:indication |
mixed dyslipidemia
primary hyperlipidemia |
| gptkbp:ingredients |
C22 H30 N4 O4 S
|
| gptkbp:interacts_with |
none significant
|
| gptkbp:invention |
patented
|
| gptkbp:is_effective_against |
significant reduction in LDL
|
| gptkbp:is_monitored_by |
lipid levels
|
| gptkbp:is_used_for |
lowering LDL cholesterol
|
| gptkbp:manager |
subcutaneous
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:United_States |
| gptkbp:pharmacokinetics |
long half-life
reduces LDL levels |
| gptkbp:population |
adults
|
| gptkbp:price |
high
|
| gptkbp:provides_information_on |
NICE guidelines
AHA/ ACC guidelines ESC/ EAS guidelines |
| gptkbp:receives_funding_from |
public and private sources
|
| gptkbp:research |
real-world evidence studies
long-term safety studies |
| gptkbp:research_areas |
gptkb:hospital
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
fatigue
muscle pain nausea liver enzyme elevation injection site reactions hypersensitivity reactions kidney function impairment |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
PCS K9 protein
|
| gptkbp:traded_on |
gptkb:Leqvio
|
| gptkbp:treatment |
reduced cardiovascular events
|
| gptkbp:type_of_care |
high adherence rates
|
| gptkbp:weight |
450.56 g/mol
|
| gptkbp:bfsParent |
gptkb:Leqvio
|
| gptkbp:bfsLayer |
6
|